Histological Findings, Genotype Distribution and Percentage of Patients Fulfilling the Treatment Criteria among Patients with Chronic Hepatitis C Virus Infection in a Single Swedish Centre

Scandinavian Journal of Gastroenterology

Volumn 39, Issue 2, 2004, Pages 164-167

  Hollander, A ^a   Glaumann, H ^a   Weiland, O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Genotype; Hepatitis C virus; Histology; Treatment criteria

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DRUG USE; FEMALE; GENOTYPE ENVIRONMENT INTERACTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX RATIO; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; SWEDEN;

EID: 1342288788     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310008115     Document Type: Article

References (16)

1. Nosbaum J, Pol S, Nalpas B, Landais P, Berthelot P, Bre'chot C, and the Collaboratory Study Group. Hepatitis C virus type 1b infection in France and Italy. Ann Int Med 1995;122:161-8.
2. Westin J, Lindh M, Lagging LM, Norkrans G, Wejstal R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999;31: 355-8.
3. Weiland O, Braconier J, Frydén A, Norkrans G, Reichard O, Uhnoo I, and the Swedish Hepatitis Study Group. Influence of pretreatment viral load and genotype, ALT and virological response week 12, and length of interferon alfa treatment on sustained virological outcome in patients with chronic hepatitis C infection. Scand J Infect Dis 1999;31:115-8.
4. Poynard T, Marcelin P, Lee S, Niederau C, Minuk G, Ideo G, et al, for the International Hepatitis Interventional Therapy Group. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
5. McHutchison J, Gordon S, Schiff E, Schiffman M, Lee W, Rustgi V, et al, for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339: 1485-92.
6. Weiland O. Interferon and ribavirin combination therapy: indications and schedules. Geneva: Forum; 2000;10:22-8.
7. Wejstal R, Fischler B, Glaumann H, Norkrans G, Reichard O, Sonnerborg A, et al. Chronic hepatitis C - Swedish experts' meeting recommends combination treatment. Scand J Infect Dis 2000;32:465-70.
8. Anonymous. Consensus Statement, EASL International Consensus Conference on hepatitis C. J Hepatology 1999;30:956-61.
9. Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [In Process Citation]. Lancet 2001;358 (9286):958-65.
10. Fried M, Shiffman M, Reddy K, Smith C, Marinos G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection [In Process Citation]. N Engl J Med 2002;347: 975-82.
11. Anonymous. NIH consensus development conference statement: management of hepatitis C 2002 (June 10-12, 2002). Hepatology 2002;36 Suppl 1:S3-S20.
12. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259-66.
13. Yun Z, Lara C, Johansson B, Lorenzana RI, Sonnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996;49:155-60.
14. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999;6:237-12.
15. Seeff L. Natural history of hepatitis C. Hepatology 1997;6 Suppl 1:21S-8S.
16. Wejstål R, Alaeus A, Fischler B, Reichard O, Uhnoo I, Weiland O. Chronic hepatitis C: updated Swedish consensus. Scand J Infect Dis 2003;35:445-51.